Management confirms expectations for 2013
Waregem (Belgium) / Rotterdam (The Netherlands)[1], 9 April 2013 -In the first quarter of 2013, the consolidated turnover of Arseus increased 1.7% to € 133.3 million.
The evolution of turnover[2] per division is as follows:
Ger van Jeveren, CEO of Arseus: “We can look back at a satisfactory first quarter of 2013. Fagron and Corilus showed continuing strong performance, while the development of turnover at Healthcare Solutions and Healthcare Specialties was influenced by the ongoing process of optimisation of the product portfolio and by the lack of clarity and uncertainty in Western Europe surrounding the reimbursement of dental charges.
The continuous strategic focus on innovative products and concepts with substantial added value has had an impact on the development of Arseus’ turnover during the first quarter of 2013. The discontinuation of products and distributions with a lower margin at Fagron, Healthcare Specialties and Healthcare Solutions had an effect of € 4 million on turnover in the first quarter of 2013. Consistent optimisation of the product portfolio has resulted in an increase of Arseus’ gross margin in the first quarter of 2013 by 2.5 percentage points compared to the same period in 2012.
We look to the future with great confidence and consequently confirm the expectations for 2013 that we announced earlier.”
[1] This press release was sent out by Arseus NV and Arseus BV.
[2] Unaudited management figures.
Please open the link below for the full press release: